More Efficient, Evidence-Based PA Process Could Benefit Genomic Testing

With more than 77,000 genetic tests available and new tests constantly coming to market, it can be difficult for payers and providers alike to keep track of not just what the products are but also how effective they can be. To make sure that beneficiaries are receiving appropriate testing, many payers have prior authorization (PA) in place. But as the process often can be burdensome for providers, a more evidence-based, streamlined approach to coverage could authorize necessary genomic testing with greater efficiency.

AHIP conducted a study from February through April 2022 on PA practices and received responses from 26 health plans with 122 million commercial covered lives. Along with specialty drugs, genetic testing was the only other treatment that respondents said was subject to PA 100% of the time.